Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
March 05 2024 - 1:30AM
Strasbourg (France), Tokyo (Japan) and
Waltham, Mass (USA), March 5th, 2024, 7:30 am CET -
Transgene (Euronext Paris: TNG), a biotech company that designs and
develops virus-based immunotherapies for the treatment of cancer,
NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI
technologies and BostonGene Corporation (BostonGene), a leading
company in AI-based molecular and immune profiling, today announced
the expansion of their collaboration for the randomized Phase I/II
trial of TG4050, an individualized therapeutic vaccine for patients
with head and neck cancers.
BostonGene is partnering with NEC and Transgene
to continue performing tumor molecular profiling and
microenvironment analysis and provide high-throughput sequencing
services. The partnership with BostonGene will enable fast
turnaround of next-generation sequencing (NGS) data, and
sophisticated analytics will enable comprehensive profiling of
patient immune contexture.
TG4050, a personalized immunotherapy designed to
stimulate the immune system of patients to induce a neoantigen
specific T-cell response that can recognize and destroy tumor
cells, is based on Transgene’s myvac® platform and powered by NEC’s
AI-driven Neoantigen Prediction System.
“Our collaboration with BostonGene has provided
in-depth information on patient phenotypes in the Phase I trial. It
has allowed us to understand the baseline status of our patients
and how the tumor micro-environment (TME) might evolve following
treatment,” said Dr. Alessandro Riva, Chairman and CEO of
Transgene.
“The combined expertise of Transgene, NEC and
BostonGene will continue to provide a streamlined pipeline for the
timely delivery of patient-tailored vaccines as well as data to
guide the future development of new personalized treatment options,
elevating the standard of care for head and neck cancer patients,”
said Masamitsu Kitase, Corporate SVP and Head of the
Healthcare and Life Sciences Division at NEC
Corporation.
“We are committed to supporting Transgene and
NEC as they advance these clinical trials,”
said Nathan Fowler, MD, Chief Medical Officer at
BostonGene. “Our molecular and immune profiling techniques
comprehensively analyze the tumor, microenvironment, and immune
system to identify key predictors of response to TG4050, ultimately
improving treatment outcomes.”
About myvac®myvac® is a viral
vector (MVA – Modified Vaccinia Ankara) based, individualized
immunotherapy platform that has been developed by Transgene to
target solid tumors. myvac®-derived products are designed to
stimulate the patient’s immune system to recognize and destroy
tumors using their own cancer specific genetic mutations. Transgene
has set up an innovative network that combines bioengineering,
digital transformation, established vectorization know-how and
unique manufacturing capabilities. Transgene has been awarded
“Investment for the Future” funding from Bpifrance for the
development of its platform myvac®. TG4050 is the first
myvac®-derived product being evaluated in clinical trials. Click
here to watch a short video on myvac®.
About TG4050TG4050 is an
individualized immunotherapy being developed for solid tumors that
is based on Transgene’s myvac® technology and powered by NEC’s
longstanding artificial intelligence (AI) and machine learning (ML)
expertise. This virus-based therapeutic vaccine encodes neoantigens
(patient-specific mutations) identified and selected by NEC’s
Neoantigen Prediction System. The prediction system is based on
more than two decades of expertise in AI and has been trained on
proprietary data allowing it to accurately prioritize and select
the most immunogenic sequences.TG4050 is designed to stimulate the
immune system of patients in order to induce a T-cell response that
is able to recognize and destroy tumor cells based on their own
neoantigens. This individualized immunotherapy is developed and
produced for each patient.Initial immunological and clinical data
from the ongoing Phase I trial in the adjuvant treatment of
HPV-negative head and neck cancers were presented at several
conferences in 2023 and are very encouraging.
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.frFollow us on social
media: X (previously-Twitter): @TransgeneSA – LinkedIn:
@Transgene
About NEC CorporationNEC
Corporation has established itself as a leader in the integration
of IT and network technologies while promoting the brand statement
of “Orchestrating a brighter world.” NEC enables businesses and
communities to adapt to rapid changes taking place in both society
and the market as it provides for the social values of safety,
security, fairness and efficiency to promote a more sustainable
world where everyone has the chance to reach their full potential.
For more information, visit NEC at https://www.nec.com and NEC’s AI
Drug Development Business at
https://www.nec.com/en/global/solutions/ai-drug/.
About
BostonGene Corporation BostonGene has a mission to provide
transformative, AI-integrated molecular analytics and biomarker
discovery for precision matching of therapies to improve the lives
of patients living with cancer and other immune-related diseases.
BostonGene’s service model provides customized client solutions
using a multi-omic approach prioritized for real-world impact,
including optimized standard-of-care therapies, accelerated
research and cost-effective, measurable results. BostonGene’s
tests reveal key drivers of each patient’s unique disease profile,
including an in-depth profile of the immune microenvironment,
actionable mutations, biomarkers of response to diverse therapies,
and recommended therapies. Through these comprehensive analyses,
BostonGene’s tests generate a personalized roadmap for therapeutic
decision-making for each patient. For more information, visit
BostonGene at http://www.BostonGene.com.
Contacts:
Transgene
Lucie
LarguierVP, Corporate Communications &
IR+33 (0)3 88 27 91 04investorrelations@transgene.fr |
Media: MEDiSTRAVA Consulting Frazer
Hall/Sylvie Berrebi+44
(0)203 928 6900transgene@medistrava.com |
NECJoseph
Jasper+81-3-3798-6511j-jasper@nec.com
BostonGeneErin
O’Reilly+1-617-283-2285Erin.Oreilly@BostonGene.com
Transgene disclaimerThis press
release contains forward-looking statements, which are subject to
numerous risks and uncertainties, which could cause actual results
to differ materially from those anticipated. The occurrence of any
of these risks could have a significant negative outcome for the
Company’s activities, perspectives, financial situation, results,
regulatory authorities’ agreement with development phases, and
development. The Company’s ability to commercialize its products
depends on but is not limited to the following factors: positive
pre-clinical data may not be predictive of human clinical results,
the success of clinical studies, the ability to obtain financing
and/or partnerships for product manufacturing, development and
commercialization, and marketing approval by government regulatory
authorities. For a discussion of risks and uncertainties which
could cause the Company’s actual results, financial condition,
performance or achievements to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
(“Facteurs de Risque”) section of the Universal Registration
Document, available on the AMF website (http://www.amf-france.org)
or on Transgene’s website (www.transgene.fr). Forward-looking
statements speak only as of the date on which they are made, and
Transgene undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the
future.
- 20240305_Transgene_NECBio_BostonGene_Press_Release_EN
Transgene (EU:TNG)
Historical Stock Chart
From May 2024 to Jun 2024
Transgene (EU:TNG)
Historical Stock Chart
From Jun 2023 to Jun 2024